CSIMarket Company Name, Ticker, Customers, else..
 
Medicinova Inc   (NASDAQ: MNOV)
 
Price: $1.5613 $-0.06 -3.623%
Day's High: $1.6232000589370728 Week Perf: 8.42 %
Day's Low: $ 1.55 30 Day Perf: 14.8 %
Volume (M): 39,526 52 Wk High: $ 1.96
Volume (M$): $ 0 52 Wk Avg: $1.40
Open: $1.62 52 Wk Low: $1.17



 Market Capitalization (Millions $) 77
 Shares Outstanding (Millions) 49
 Employees 6
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Business Description


Medicinova Inc. is a biopharmaceutical company headquartered in La Jolla, California. The company is focused on the development and commercialization of innovative therapeutics for the treatment of serious diseases with high unmet medical needs.

Medicinova was founded in 2000 by Dr. Yuichi Iwaki, and has since grown to become a leading player in the field of biopharmaceutical research and development. The company's research projects are primarily focused on developing therapeutics for the treatment of neurological and autoimmune diseases, with an emphasis on neurological disorders such as multiple sclerosis and neurological pain.

Among their most notable products is MN-166 (ibudilast), which has shown promising results in the treatment of a range of neurological disorders, including multiple sclerosis, neuropathic pain, and addiction. Medicinova also has a pipeline of other promising drug candidates, including MN-001 (tipelukast) for the treatment of nonalcoholic steatohepatitis (NASH) and MN-221 (bedoradrine), a selective beta-2 adrenergic receptor agonist for the treatment of acute exacerbations of asthma.

Since its founding, Medicinova has maintained a strong commitment to advancing the development of safe and effective therapeutics for the treatment of debilitating diseases. The company has received numerous awards for its contributions to the biopharmaceutical industry, including the Frost & Sullivan Global Product Line Strategy Leadership Award for MS Therapeutics in 2018.

Medicinova's team of scientists, researchers, and industry experts are driven by a shared commitment to achieving breakthroughs in the treatment of serious diseases, making the company a leader in the biopharmaceutical space.


   Company Address: 4275 Executive Square La Jolla 92037 CA
   Company Phone Number: 373-1500   Stock Exchange / Ticker: NASDAQ MNOV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        2.85% 
MRK        1.8% 
OGN        0.11% 
PFE        1.81% 
TEVA        0.7% 
VRTX        1.65% 
• View Complete Report
   



Clinical Study

A New Dawn for ALS MediciNovas COMBAT-ALS Trial Brings Hope to Patients,

Published Wed, Aug 27 2025 8:55 AM UTC

Unveiling Hope: MediciNova s Milestone in ALS Treatment Through COMBAT-ALS TrialAmyotrophic Lateral Sclerosis (ALS) remains one of the most formidable challenges in neurology today. Characterized by the degeneration of motor neurons leading to progressive muscle weakness, ALS has no cure, leaving patients and their families in a state of uncertainty. However, the advent of ...
Clinical Study

Exploring the Expanded Access Program for MN-166 in Amyotrophic Lateral Sclerosis Insights from MediciNovas First Pa...

Published Wed, Apr 9 2025 6:39 AM UTC

The landscape of drug development in neurodegenerative diseases is continually evolving, marked by innovative approaches such as the Expanded Access Program (EAP). This article analyzes the recent enrollment of the first patient in an EAP trial evaluating MN-166 (ibudilast) for patients with amyotrophic lateral sclerosis (ALS) by MediciNova, Inc. In light of the competing b...
Clinical Study

Promising Interim Findings from MediciNovas Phase 2/3 Trial of MN-166 in ALS Presented at International Symposium

Published Thu, Dec 5 2024 11:00 PM UTC

: MediciNova, Inc. a biopharmaceutical firm listed on both NASDAQ and the Tokyo Stock Exchange, has shared an update regarding its ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) for treating Amyotrophic Lateral Sclerosis (ALS). This announcement was made in anticipation of MediciNova s presentation at the 35th International Symposium on ALS/MND, scheduled for Decemb...
Clinical Study

MediciNovas Corporate Update Navigating Challenges and Strategic Development in ALS Treatment

Published Tue, Nov 19 2024 2:01 PM UTC

This article presents a overview of MediciNova Inc’s recent corporate progress outlined by CEO Yuichi Iwaki, amidst its financial performance in the evolving therapeutic landscape for Amyotrophic Lateral Sclerosis (ALS). The focus will be on the implications of the NIH-funded Phase 2-3 Expanded Access study related to the COMBAT-ALS trial and the company s ongoing fina...
Management Announcement

MediciNova on the Brink: Navigating Legal Settlements and Clinical Ambitions Amid Financial Strains

Published Mon, Nov 11 2024 11:00 PM UTC

In a noteworthy turn of events for MediciNova, Inc. a biopharmaceutical company based in La Jolla, California, the firm has received notification regarding monetary damages stemming from a patent settlement involving Sanofi and Novartis. This development, announced on November 11, 2024, indicates that MediciNova stands to gain a financial boost from this settlement, although...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 5.78
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 83.49
Price to Sales (Expected) -
Price to Book 2.06
PEG (TTM) 0.17

Financial Strength Current
Quick Ratio 8.58
Working Capital Ratio 8.75
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0.27 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) -
Cash 0.52 $
Book Value 0.76 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 153,413
Net Income per Employee (TTM) -1,792,175
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -554.31 %
Net Margin (MRQ) -504.79 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Medicinova Inc's Segments
Member    140.83 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.